DISSOLUTION - USP–NF | USP-NF
ing texts of the European Pharmacopoeia and/or the Japa-37±0.5° during the test and keeping the bath fluid in con-nese Pharmacopoeia. These pharmacopeias have undertakenstant, smooth motion. No part of the assembly, including not to make any unilateral change to this harmonized the environment in which the assembly is placed, contrib-
Download DISSOLUTION - USP–NF | USP-NF
Information
Domain:
Source:
Link to this page:
Documents from same domain
MONOGRAPHS (USP) - uspnf.com
www.uspnf.comProcedure—Transfer a sufficient portion of Test solution A and Test solution B to separate test tubes of colorless, transparent, neutralglass withaflatbaseandaninternaldia-
Stearic Acid M - uspnf.com
www.uspnf.comStage 6 Harmonization Official May 1, 2016 Stearic 1. = molecular weight of potassium hydroxide, Stearic Acid M r 56.11 NF34 Acceptance criteria: 194–212 Portions of this monograph that are national USP text, and • C. The retention times of the major peaks of the Sample are not part of the harmonized text, are marked with solution correspond …
Injections and Implanted Drug Products (Parenterals ...
www.uspnf.comLarge-volume injections for single-dose infusion, small-Aqueous vehicles—Aqueous vehicles must meet the require- volume injections, and pharmacy bulk packages (PBPs) arements of 〈151〉 or 〈85〉, whichever is specified in the mono-
1092 THE DISSOLUTION PROCEDURE: DEVELOPMENT AND …
www.uspnf.comBRIEFING 1092 The Dissolution Procedure: Development and Validation, USP 36 page 735. This general information chapter is proposed for revision by the …
Compendial Approvals for USP42-NF37 1S
www.uspnf.comCompendial Approvals for USP42-NF37 1S Category Monograph Title Monograph Section Scientific Liaison Revision
<788> PARTICULATE MATTER IN INJECTIONS - uspnf.com
www.uspnf.comsize. The definition for particle-free water is provided in Reagent Specifications under Reagents, Indicators and Solution section. The apparatus is calibrated using dispersions of …
General Notices and Requirements - uspnf.com
www.uspnf.com4 General Notices USP 32 3.10.10. Applicability of Standards to Drug Products, Drugarticle.For general requirements relating to specific monograph Substances, and Excipients sections, see section 5, Monograph Components. The applicable USP or NF standard applies to any article mar-Because monographs may not provide standards for all relevant keted in the United States that (1) is …
Levetiracetam Tablets - uspnf.com
www.uspnf.comRevision Bulletin 2 Levetiracetam Official May 1, 2011 Sample solution: Pass a portion of the solution under test Mode: LC through a suitable filter. Dilute an aliquot with Medium to Detector: UV 200 nm obtain a concentration similar to that of the Standard Column: 4.6-mm × 25-cm; 4-µm packing L1 solution.
Residual Solvents: ICH Q3C Impurities: Residual Solvents
www.uspnf.comheadspace analysis, solid-phase microextraction, and direct injection of solution containing bulk drug substance or drug product into the gas chromatograph. zIn conclusion, gas chromatograph-based procedures will continue to dominate residual solvent testing because of its specificity for
General Chapter Injections Correction - USP-NF
www.uspnf.comtherapeutic efficacy or with the responses to the specified assaysmore than 1 L are labeled to indicate that the contents are not in- ... tices and Antimicrobial Effectiveness Testing 〈51〉). remains uncovered for its full length or circumference to permit in- ... the section Preservation, Packaging, Storage, and Labeling of the
Related documents
EUROPEAN PHARMACOPOEIA 5
uspbpep.comEUROPEAN PHARMACOPOEIA 5.0 2.9.1. Disintegration of tablets and capsules 2.9. PHARMACEUTICAL TECHNICAL PROCEDURES 01/2005:20901 2.9.1. DISINTEGRATION OF TABLETS AND CAPSULES The disintegration test determines whether tablets or capsules disintegrate within the prescribed time when placed in a liquid medium in the experimental …
2.9.5. UNIFORMITY OF MASS OF SINGLE-DOSE PREPARATIONS
uspbpep.com2.9.5. Uniformity of mass of single-dose preparations EUROPEAN PHARMACOPOEIA 6.0 01/2008:20905 2.9.5. UNIFORMITY OF MASS OF SINGLE-DOSE PREPARATIONS Weigh individually 20 units taken at random or, for single-dose preparations presented in individual containers, the contents of 20 units, and determine the average mass.
2.9.40. UNIFORMITY OF DOSAGE UNITS
www.drugfuture.com2.9.40. Uniformity of dosage units EUROPEAN PHARMACOPOEIA 7.0 Table 2.9.40.-1. – Application of Content Uniformity (CU) and Mass Variation (MV) test for dosage forms Dosage forms Type Sub-Type Dose and ratio of active substance ≥25 mg and ≥25 per cent <25mgor<25percent Tablets uncoated MV CU coated film-coated MV CU others CU CU …
General Concepts in the European Pharmacopoeia
www.ema.europa.eucapsules, parenteral ... European Pharmacopoeia … has been prepared by a method liable to leave impurities not controlled in the pharmacopoeia monograph, these impurities and their maximum tolerance limits must be declared and a suitable test procedure must
The European Pharmacopoeia and Your Logo certificates of ...
www.ema.europa.euThe European Pharmacopoeia and certificates of suitability (CEP) General monographs on dosage forms • Contain requirements common to all dosage forms of the type defined (tablets, capsules, parenteral preparations, etc.) • Classified by pharmaceutical form/route of …
á701ñ DISINTEGRATION
www.usp.orgá701ñ DISINTEGRATION Change to read: This general chapter is harmonized with the corresponding texts of the European Pharmacopoeia and/or the Japanese Pharmacopoeia.The texts of these pharmacopeias are therefore interchangeable, and the methods of the European Pharmacopoeia and/or the Japanese Pharmacopoeia may be used for demonstration of …
DISINTEGRATION - USP–NF | USP-NF
www.uspnf.comand the methods of the European Pharmacopoeia stroke the wire mesh remains at least 15 mm be-and/or the Japanese Pharmacopoeia may be used ... states that the tablets or capsules are intended forside diameter of 20.7 to 23 mm and a wall 1.0 to use as troches, or are to be chewed, or are designed 2.8 mm thick; the tubes are held in a vertical ...